

# ALLERGY & RHINOLOGY

*Editor-in-Chief:*

**Alan Gaines, MD**

*Contributing Editor*

**Russell Settupane, MD**

*Section Editor – Pathology Quiz Case*

**Bradford A. Woodworth, MD**

Phone: (401)331-2510 FAX: (401)331-0223 Email: [oceanside@oceansidepubl.com](mailto:oceanside@oceansidepubl.com)

*Allergy & Rhinology (A&R) is an Open Access journal, which publishes under the [Creative Commons License Deed](#). In the event the Work is published, the author(s) agree to and accept the terms of the [Creative Commons License Deed: \(Attribution - Non-Commercial - 4.0 Unported \(CC BY-NC 4.0\)\)](#) and retain the copyright to their Work as per the [Publication Rights Agreement](#) which also serves to grant the Publisher exclusive license and rights for all commercial use regarding the Work.*

*All submitted manuscript submissions will be subject to peer review and if accepted will be subject to a Manuscript Processing Fee (MPF) prior to publication (see page 5). A&R utilizes an online system of manuscript submission, editing and review. This system allows authors to submit their Work online and check on the status of the review process. To access the electronic system, visit <http://ar.msubmit.net>. This technology requires all manuscript files be uploaded separately as follows:*

- 1.) cover letter
- 2.) manuscript (including title page, abstract, text, references and figure **legends** only) *excluding table and figure files*
- 3.) tables (can be consolidated into one “tables” file or uploaded separately)
- 4.) figures (preferably uploaded separately)

The Publication Rights Agreement must be executed and Conflict of Interest forms must be submitted in order to be considered for peer review. Forms may be sent via electronic transmission, email or fax. To submit electronically, please visit the submission site and upload under the manuscript submission page (<http://ar.msubmit.net>)

Forms may also be downloaded: [http://allergyandrhinology.com/JAR\\_pub\\_forms.pdf](http://allergyandrhinology.com/JAR_pub_forms.pdf)

Electronic manuscript submission is a four-step process that is described step-by-step on the [ar.msubmit.net](http://ar.msubmit.net) site. *Allergy & Rhinology* does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office. Please contact the editorial offices with any questions regarding the submission process.

**MANUSCRIPT PREPARATION GUIDELINES:** *Please note: Failure to follow these format instructions may result in the manuscript being returned to the author(s) for revision prior to review.*

**SELECTING A MANUSCRIPT TYPE:** *When uploading your completed manuscript, you will be required to designate a manuscript type. The following are guidelines for choosing:*

- **Original manuscript:** Provides the results of original laboratory and/or clinical research. Components

indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures)

Word Limit: 2500 words (exceptions allowed under special circumstances)

- **Review:** Manuscript that provides a review of previously published literature. Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures) Word limit: 3000 words
  - **Letters to the Editor:** Letters should be a brief communication commenting on an article recently published in the Journal. Letters to the editor will be reviewed by the Editor(s) and peer-reviewed. Letters to the Editor are limited to 500 words and 5 references. Because letters to the editor are indexed and can be cited, key words are also required. Letters to the Editor will be published exclusively online, with exceptions per the Editor.
  - **Case Reports:** *Allergy & Rhinology* will review case reports that are truly unique and have an exceptional teaching value.
  - **Expedited Manuscript Service:** This is a fee-based option requiring submission of the [EMS Request Form](#). The EMS option is for authors who consider the publication of their manuscripts to be time sensitive or who have specific publication deadlines to meet. EMS expedites both the peer review process and the publication date of accepted manuscripts See [Author Instructions](#) for more information.
- ✓ **Cover letter:**
- Declare intentions to publish in *A&R* and confirm you have not submitted elsewhere.
- ✓ **Title page:**
- Include full a non-declarant, relevant, and concise (no more than 15 words) title in sentence format (only capitalize proper nouns). Do not include abbreviations or use trade names in the title.
  - First name, middle initial, last name of each author with highest academic degrees included (do not include fellowships). All contributing authors should be listed including any professional writing assistance.
  - Name of Departments and Institutions to which Work should be attributed; (*see Conflict of Interest below*)  
Disclaimers if any, should be limited to those pertaining to this Work. Please reconcile conflicts of interest for each author to match those on your conflict of interest form. See Journal Statements below regarding conflicts of interest.
  - If this Work is supported through NIH funding, this must be noted in the footnote for PMC deposits
  - Provide acknowledgment of any and all financial support/funding. If no external support, please indicate if the Work is self-funded. (*see Conflict of Interest below*)
  - As per ICMJE guidelines (<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/protection-of-research-participants.html>), in studies involving human subjects, or human derived data, it is required that a statement describing approval by the Institutional Review Board (IRB), including the full name of the institution which provided the IRB approval and the approval number if available. This IRB statement as well as statements regarding Informed Consent and/or animal rights should also be included in the methods section of the manuscript. See Journal Statements below regarding Informed Consent and Ethics Committee Review approval
  - **Key Words (10 key words are mandatory):** Selecting appropriate key words is essential to your research being discovered by others. Keywords should be mentioned in the abstract.

- Include date of presentation at scientific meeting (if any)
- Include corresponding author’s telephone number, FAX number and/or **e-mail address**

✓ **Abstract:** All manuscript types with the exception of the Letters to the Editors should include a structured abstract, **no longer than 300 words**, to precede article. Only include acronyms or abbreviations if the phrase appears more than three times in the abstract. The abstracts should NOT include brand names, trademarks or references. Clinical trial registration numbers should be listed last in the abstract. Structure abstract into the following sections:

*Background* – Describe the problem that prompted the study

*Objective* – Describe the purpose of the study

*Methods* – Describe how the study was conducted

*Results* – Describe the most important findings

*Conclusion* - Describe the most important conclusion drawn from the study

✓ **Length** - Specified length for all manuscript types excluding Letters to the Editor are listed below

*Text - Original* – no more than 2500 words (with rare exception), not including abstract and references

*Review* – no more than 3000 words (with rare exception), not including abstract and references

*Text Formatting* - Manuscripts should be typed double-spaced in a standard font such as Times New Roman, Arial, Courier, or Helvetica, in size 12. Text should be written in clear and concise English with proper use of grammar and syntax. Please add line numbers to your text so that reviewers can most accurately direct their feedback. Authors whose primary language is not English should obtain assistance with writing to avoid grammatical problems. Several independent services for authors in the Science, Technical and Medical fields are available online and include:

US based:	<a href="http://www.biomeditor.com/">www.biomeditor.com/</a>
	<a href="http://www.biosciencewriters.com/">www.biosciencewriters.com/</a>
	<a href="http://www.bostonbioedit.com">www.bostonbioedit.com</a>
	<a href="http://www.academicword.com">www.academicword.com</a>
	<a href="http://www.writescienceright.com">www.writescienceright.com</a>
	<a href="http://www.manuscriptedit.com">www.manuscriptedit.com</a>
UK based:	<a href="http://www.internationalscienceediting.com/">www.internationalscienceediting.com/</a>
Asia Pacific India:	<a href="http://www.asiascienceediting.com/">www.asiascienceediting.com/</a>
Asia:	<a href="http://www.edanzediting.com/ajr">www.edanzediting.com/ajr</a>
Australia:	<a href="http://www.oleng.com.au/">www.oleng.com.au/</a>
Philippine:	<a href="http://www.prof-editing.com">www.prof-editing.com</a>

*Please note: These few sites are only listed as a convenience and are **not an endorsement** of their products. They are in no way affiliated with the journal and use of their services will not guarantee acceptance of a manuscript.*

✓ **Acknowledgment:** General acknowledgments for consultations, statistical analysis and such should be listed at the end of the text before the References. Include full names of individuals. Any and all **acknowledgments of funding must be disclosed on the title page.**

✓ **References:** Refer to [End Note](#) for proper reference structure; enter “oceanside” in the “publisher” search window to find the proper format for A&R. References in the text should be superscript numbers in order of appearance. Manuscripts in preparation, personal communications, or other unpublished information should *not* be cited in the reference list but may be mentioned in the text in parentheses. References with more than three authors should be presented as the first three authors followed by et al.

Please follow format below, e.g.:

1. Berger WE and Meltzer EO. Intranasal spray medication for maintenance therapy of allergic rhinitis. *Am J Rhinol Allergy* 29:273–282, 2015.
2. Hsu AK, Singh A, Bury S, et al. Endoscopic cerebrospinal fluid leak closure in an infected field. *Am J Rhinol Allergy* 29:305–308, 2015
3. Al-Qudah M. Efficacy of lidocaine with or without epinephrine in rigid nasal endoscopy. *Am J Rhinol Allergy* 28:520–522, 2014.
4. Centers for Disease Control and Prevention. What parents need to know about enterovirus D68. Available online at <http://www.cdc.gov/features/evd68/>; accessed November 17, 2014.

✓ **Tables:** Tables may be placed within the manuscript or uploaded as separate files (preferred .doc format). If table is included in manuscript file, place after the References section, one table per page. Any abbreviations included in the table should be defined at the bottom of the table. If the table is being republished with permission, proof of permission must be faxed to the editorial office.

✓ **Figure legends:** Figure legends should be typewritten, double-spaced and listed (numbered) on a separate page after the tables. They should not appear on the figures. Include figure titles at the beginning of the legend preferably in bold text. Any abbreviations included in the figures should be defined at the bottom of the figure.

✓ **Figures, and illustrations:** Illustrations included in manuscripts must be submitted in electronic format along with the rest of the manuscript. Each figure should be submitted as a **separate electronic file - not embedded in the manuscript text file**. See Cadmus guidelines for submitting digital art at <http://cpc.cadmus.com/da/guidelines.asp>. Figure file preference is .tif, .jpeg, .eps. Proof of permission must be faxed to the editorial office for any figures being republished with permission. Proof of informed consent (signed releases) must be faxed to the editorial office for any and all photographs of identifiable persons. Unless it is the authors desire to publish the figures in color, the figures should be optimized for black and white publication.

✓ **Publishing forms:**

1. **Publication Rights Agreement:** MANUSCRIPTS WILL NOT BE REVIEWED UNLESS ACCOMPANIED BY A PUBLICATION RIGHTS AGREEMENT FORM SIGNED BY EACH AND EVERY AUTHOR. The author(s) agree to and accept the terms of the [Creative Commons License Deed: \(Attribution - Non-Commercial 4.0 Unported \(CC BY-NC 4.0\)\)](#) and retain the copyright to their Work as per the [Publication Rights Agreement](#) which also serves to grant the Publisher exclusive license and rights for all commercial use regarding the Work.
2. **Conflict of Interest form (per ICJME guidelines):** *Allergy & Rhinology* requires all authors listed on the title page of the manuscript to make the following disclosures:
  1. On the title page of the manuscript, authors must acknowledge:
    - a. all funding sources that supported their Work and
    - b. all institutional or corporate affiliations of each author
  2. Also, **all** authors must submit a separate form (one for each author) listing the existence of any and all commercial associations that might pose a conflict of interest such as: consultant arrangements, stock or other equity ownership, patent licensing arrangements, or payments for conducting or publicizing the study. MANUSCRIPTS WILL NOT BE REVIEWED UNLESS ACCOMPANIED BY A CONFLICT OF INTEREST

DISCLOSURE FORM SIGNED BY EACH AND EVERY AUTHOR. Disclosures will be held in strict confidence during the review process. If the paper is accepted for publication, the Editor will determine how any conflict of interest should be disclosed.

- Blank Publication Rights Agreement forms as well as Conflict of Interest forms may be downloaded at [http://www.allergyandrhinology.com/JAR\\_pub\\_forms.pdf](http://www.allergyandrhinology.com/JAR_pub_forms.pdf) Completed forms should be uploaded at the time of submission. Please indicate the file type as “publication forms” and attach to your submission.

### Manuscript Processing Fee (MPF) Schedule and Guidelines

Once an article has been accepted for publication, it cannot be scheduled to an issue until the MPF has been paid. Simply go to [www.allergyandrhinology.com](http://www.allergyandrhinology.com) and click on the “Pay Manuscript Processing Fee” button. The fee may be paid via PayPal or by check according to the following fee schedule. Please contact the Editorial office if you have any questions at [publication@oceansidepubl.com](mailto:publication@oceansidepubl.com)

Article page count *	Fee **
1-4 pages	\$600.00 USD
5-8 pages	\$800.00 USD
9-12 pages	\$1,000.00 USD
Letters to the Editor	\$100.00 USD per page

\*\* Page count determined post- production, at time of page proofing.

\*\* Application waiver for final fee determination for developing countries, (MPF WAIVER).

### Allergy & Rhinology Journal Statements:

- Author Responsibilities-Authors are responsible to disclose all relevant conflicts of interest.

Public trust in the scientific process and the credibility of published articles depend in part on how transparently conflicts of interest are handled during the planning, implementation, writing, peer review, editing, and publication of scientific Work.

A conflict of interest exists when professional judgment concerning a primary interest (such as patients’ welfare or the validity of research) may be influenced by a secondary interest (such as financial gain). Perceptions of conflict of interest are as important as actual conflicts of interest.

Financial relationships (such as employment, consultancies, stock ownership or options, honoraria, patents, and paid expert testimony) are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, and of science itself. However, conflicts can occur for other reasons, such as personal relationships or rivalries, academic competition, and intellectual beliefs. Authors should avoid entering in to agreements with study sponsors, both for-profit and nonprofit, that interfere with authors’ access to all of the study’s data or that interfere with their ability to analyze and interpret the data and to prepare and publish manuscripts independently when and where they choose.

- Informed Consent -Authors are required to obtain informed consent from study subjects and patients.

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the

Internet as well as in print after publication. Patient consent should be written and archived with the journal, the authors, or both, as dictated by local regulations or laws. Applicable laws vary from locale to locale, and journals should establish their own policies with legal guidance. Since a journal that archives the consent will be aware of patient identity, some journals may decide that patient confidentiality is better guarded by having the author archive the consent and instead providing the journal with a written statement that attests that they have received and archived written patient consent.

Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, authors should provide assurance, and editors should so note, that such changes do not distort scientific meaning.

3. Protection of research participants – Authors are required to obtain ethics committee review approval from the governing Institutional Review Board.

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013 (<http://www.wma.net/en/30publications/10policies/b3/index.html>). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

When reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed. Further guidance on animal research ethics is available from the International Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and Welfare: <http://www.veteditors.org/consensus-author-guidelines-on-animal-ethics-and-welfare-for-editors>